Although second-generation AR inhibitors have an influential role in the treatment of PCa patients with metastasis or advanced disease, constant clinical research and development of new generation AR degraders and alternative therapeutic modalities will broaden the treatment modalities in the disease continuum of PCa. Here, AR is linked to posterior cortical atrophy.